Tango Therapeutics (TNGX) Share-based Compensation (2020 - 2026)

Tango Therapeutics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $77.1 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 962.72% year-over-year to $77.1 million in Q1 2026; TTM through Mar 2026 was $77.1 million, a 161.95% increase from a year earlier, with the FY2025 full-year figure at $26.4 million, down 8.54% from the prior year.
• Share-based Compensation improved to $77.1 million in Q1 2026 per TNGX's latest filing, from $6.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $77.1 million in Q1 2026 and bottomed at $3.2 million in Q1 2022.
• The 5-year median for Share-based Compensation is $6.0 million (2025), against an average of $9.7 million.
• Across the five-year window, Share-based Compensation soared 160150.0% in 2022 and declined 19.86% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $3.8 million in 2022, then increased by 28.9% to $4.9 million in 2023, then jumped by 52.94% to $7.5 million in 2024, then retreated by 19.86% to $6.0 million in 2025, then surged by 1189.3% to $77.1 million in 2026.
• Per Business Quant, the three latest TNGX Share-based Compensation figures stand at $77.1 million (Q1 2026), $6.0 million (Q4 2025), and $6.6 million (Q3 2025).